

Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

Mouse Anti-Human Melanoma (MCSP) Monoclonal Antibody, APC Conjugated Clone EP-1

RRID:AB_871575

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-091-252, RRID:AB_871575

Antibody Information

URL: http://antibodyregistry.org/AB_871575

Proper Citation: Miltenyi Biotec Cat# 130-091-252, RRID:AB_871575

Target Antigen: Mouse Human Melanoma (MCSP) APC Clone EP-1

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 2-2018; manufacturer recommendations: Mouse IgG1 Flow Cytometry; Immunofluorescence; Flow cytometry; Immunofluorescence
Detection of human melanoma cells

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-117-347. (RRID:AB_2727921).

Antibody Name: Mouse Anti-Human Melanoma (MCSP) Monoclonal Antibody, APC Conjugated Clone EP-1

Description: This monoclonal targets Mouse Human Melanoma (MCSP) APC Clone EP-1

Target Organism: human

Antibody ID: AB_871575

Vendor: Miltenyi Biotec

Catalog Number: 130-091-252

Record Creation Time: 20250819T220218+0000

Record Last Update: 20250820T005430+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Human Melanoma (MCSP) Monoclonal Antibody, APC Conjugated Clone EP-1.

Warning: Discontinued: 2021

Discontinued: 2-2018; manufacturer recommendations: Mouse IgG1 Flow Cytometry; Immunofluorescence; Flow cytometry; Immunofluorescence

Detection of human melanoma cells

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-117-347. (RRID:AB_2727921).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Weidele K, et al. (2026) Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients. EMBO molecular medicine, 18(1), 297.